RenovoRx, Inc. (RNXT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
RenovoRx, Inc. (RNXT) trades at $0.95 with AI Score 25/100 (Grade F). RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for solid tumors. Market cap: $35.27M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026RNXT stock analysis for 2026: Analysts have set a consensus price target of $6.69 for RenovoRx, Inc., suggesting 605.7% upside from the current price of $0.95. The AI MoonshotScore is 25/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
RNXT: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →RenovoRx, Inc. (RNXT) Healthcare & Pipeline Overview
RenovoRx, Inc. is a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, with a focus on its lead product candidate, RenovoGem, a drug-device combination currently in Phase III trials for locally advanced pancreatic cancer, positioning it within the competitive oncology therapeutics market.
What Is the Investment Thesis for RNXT?
RenovoRx presents a focused investment opportunity within the biotechnology sector, primarily driven by the potential success of RenovoGem in treating locally advanced pancreatic cancer. The ongoing Phase III clinical trial is a critical value driver; positive results could lead to regulatory approval and subsequent commercialization. With a market capitalization of $35.27M, RenovoRx offers high-risk, high-reward potential. Key catalysts include the progression of RenovoGem through clinical trials and potential partnerships for commercialization. However, the company's negative profit margin of -994.5% and reliance on a single lead product candidate represent significant risks. Successful navigation of regulatory hurdles and securing additional funding will be crucial for RenovoRx's long-term viability.
Based on FMP financials and quantitative analysis
RNXT Key Highlights
- RenovoGem is currently in Phase III clinical trials for the treatment of locally advanced pancreatic cancer (LAPC).
- The company's gross margin stands at 70.9%, indicating strong potential profitability upon commercialization.
- RenovoRx's market capitalization is $0.04 billion, reflecting its early-stage status and growth potential.
- The company's beta of 1.22 suggests higher volatility compared to the overall market.
- RenovoRx's lead product candidate, RenovoGem, combines intra-arterial gemcitabine with the RenovoCath delivery system for targeted drug delivery.
Who Are RNXT's Competitors?
RNXT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| GTHX G1 Therapeutics, Inc. | $7.16 | +0.14% | $377.75M | 64 |
| NKTR Nektar Therapeutics | $71.62 | +0.82% | $1.40B | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RNXT's Key Strengths?
- Proprietary drug-device combination (RenovoGem).
- Targeted drug delivery technology.
- Phase III clinical trial progress.
- Experienced management team.
What Are RNXT's Weaknesses?
- Limited financial resources.
- Reliance on a single lead product candidate.
- Negative profit margin.
- Small number of employees.
What Could Drive RNXT Stock Higher?
- Completion of Phase III clinical trial for RenovoGem in locally advanced pancreatic cancer.
- Potential FDA approval of RenovoGem.
- Progress in securing strategic partnerships for commercialization.
- Expansion of clinical trials into additional cancer indications.
What Are the Key Risks for RNXT?
- Financial-distress signal — its Altman Z-Score of -0.67 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure of Phase III clinical trial for RenovoGem.
- Regulatory delays or rejection of RenovoGem.
- Competition from established pharmaceutical companies.
- Difficulty securing additional funding.
- Intellectual property challenges.
What Are the Growth Opportunities for RNXT?
- Expansion into Additional Cancer Indications: RenovoRx has the opportunity to expand the application of its RenovoCath delivery system and intra-arterial drug delivery approach to other solid tumors beyond pancreatic cancer. This could include liver cancer, colorectal cancer, and other cancers where targeted drug delivery can improve treatment outcomes. The market for targeted cancer therapies is substantial, with the global oncology market projected to reach $286 billion by 2028. The timeline for expansion depends on clinical trial results and regulatory approvals, but represents a significant long-term growth driver.
- Strategic Partnerships and Collaborations: RenovoRx can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of RenovoGem and other pipeline candidates. These partnerships could provide access to additional funding, expertise, and distribution channels. The pharmaceutical industry is increasingly reliant on collaborations with smaller biotech firms to access innovative technologies. Securing a partnership with a major player could significantly enhance RenovoRx's market position and financial resources, with potential deals materializing within the next 1-3 years.
- Advancements in Drug Delivery Technology: Continued innovation in drug delivery technology can further enhance the efficacy and safety of RenovoRx's therapies. This includes exploring new materials, coatings, and targeting mechanisms to improve drug penetration and reduce off-target effects. The drug delivery market is experiencing rapid growth, driven by the demand for more precise and personalized treatments. Investing in research and development to advance its drug delivery platform can provide RenovoRx with a competitive edge and open up new therapeutic opportunities, with ongoing research potentially yielding results within the next 2-5 years.
- Securing Orphan Drug Designation: Obtaining orphan drug designation for RenovoGem in specific patient populations can provide RenovoRx with significant regulatory and commercial benefits. Orphan drug designation provides market exclusivity, tax credits, and other incentives to develop therapies for rare diseases. This can be a particularly attractive strategy for targeting niche patient populations with unmet medical needs. The timeline for securing orphan drug designation depends on regulatory review processes, but can provide a valuable competitive advantage within 1-2 years.
- Geographic Expansion: RenovoRx has the potential to expand its market reach beyond the United States by seeking regulatory approvals in Europe and other international markets. The global market for cancer therapies is substantial, and expanding into new geographic regions can significantly increase revenue potential. This requires navigating complex regulatory pathways and establishing distribution networks in each target market. While the timeline for international expansion may be longer (3-5 years), it represents a significant long-term growth opportunity.
What Opportunities Does RNXT Have?
- Expansion into additional cancer indications.
- Strategic partnerships with larger pharmaceutical companies.
- Advancements in drug delivery technology.
- Securing orphan drug designation.
What Threats Does RNXT Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Difficulty securing additional funding.
What Are RNXT's Competitive Advantages?
- Proprietary Drug-Device Combination: RenovoGem's unique combination of intra-arterial gemcitabine and the RenovoCath delivery system provides a competitive advantage.
- Patent Protection: The company holds patents on its drug delivery technology and therapeutic formulations.
- Clinical Data: Positive clinical trial results can create a barrier to entry for competitors.
- Targeted Delivery: The ability to deliver drugs directly to the tumor site can improve efficacy and reduce side effects.
What Does RNXT Do?
RenovoRx, Inc., founded in 2009 and headquartered in Los Altos, California, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment of solid tumors. The company's core focus is on enhancing cancer treatment efficacy while minimizing systemic toxicity. Their lead product candidate, RenovoGem, is a proprietary drug-device combination designed for targeted intra-arterial delivery of gemcitabine directly to the tumor site. RenovoGem combines the chemotherapeutic agent gemcitabine with RenovoCath, a proprietary delivery system, aiming to improve drug concentration within the tumor while reducing exposure to healthy tissues. Currently, RenovoGem is undergoing a Phase III clinical trial for locally advanced pancreatic cancer (LAPC), a particularly challenging and aggressive form of the disease. The company's approach seeks to address the limitations of traditional systemic chemotherapy by delivering the drug directly to the tumor, potentially improving patient outcomes and quality of life. RenovoRx is committed to advancing its pipeline of targeted therapies to address unmet needs in cancer treatment.
What Products and Services Does RNXT Offer?
- Develops targeted therapies for solid tumors.
- Focuses on intra-arterial drug delivery to improve treatment efficacy.
- Utilizes the RenovoCath delivery system for targeted drug administration.
- Conducts clinical trials to evaluate the safety and efficacy of RenovoGem.
- Seeks regulatory approvals for its therapies.
- Aims to improve patient outcomes and quality of life in cancer treatment.
- Innovates in the field of drug delivery technology.
How Does RNXT Make Money?
- Develops and patents proprietary drug-device combinations.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA and other regulatory agencies.
- Plans to commercialize its therapies through partnerships or direct sales.
What Industry Does RNXT Operate In?
RenovoRx operates within the competitive biotechnology industry, specifically targeting the oncology therapeutics market. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from established pharmaceutical companies and other emerging biotech firms. The global oncology market is projected to reach hundreds of billions of dollars by 2026, driven by an aging population and increasing cancer incidence. RenovoRx's focus on targeted drug delivery positions it within a growing segment of the market, aiming to improve treatment efficacy and reduce side effects compared to traditional chemotherapy. Success depends on clinical trial outcomes, regulatory approvals, and the ability to secure partnerships for commercialization.
Who Are RNXT's Key Customers?
- Oncologists who treat patients with solid tumors.
- Hospitals and cancer centers that provide cancer care.
- Patients with locally advanced pancreatic cancer and other solid tumors.
Company Profile
RenovoRx, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Mountain View, US. The company is led by CEO Shaun R. Bagai. RNXT has traded publicly since 2021.
F-Score 3/9Financial Health
RenovoRx, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.67 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -87.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -32.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -34.6%, the inverse of the P/E and a quick read on earnings relative to price.
RNXT Valuation & Market Position
With a $35.27M market cap, RenovoRx, Inc. sits in the micro-cap segment of the market. Relative to its peer group, RNXT's quantitative score of 25/100 is below the peer average of 69/100.
FY2026 estForward Outlook
Wall Street analysts project RenovoRx, Inc. revenue of about $3.2M for fiscal 2026, with EPS near $-0.29. The estimate reflects 3 contributing analysts.
RNXT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in RenovoRx's future prospects, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative nature of their targeted therapies and the potential market disruption they could cause.
- Recent partnerships and collaborations have generated excitement, showcasing the company's ability to leverage external expertise and resources effectively.
- Analysts have noted increasing interest in RenovoRx's pipeline, particularly regarding its novel approach to cancer treatment, which could attract more investors.
Bear Case
- Concerns about the competitive landscape persist, as established players in the oncology space continue to dominate, raising questions about RenovoRx's market entry.
- Recent social sentiment reflects skepticism about the company's ability to scale operations effectively, especially in a challenging regulatory environment.
- Some community members express doubts about the sustainability of RenovoRx's business model, given the high costs associated with drug development and commercialization.
- Market perception remains cautious, with discussions highlighting the potential risks associated with clinical trial outcomes that could impact investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
RNXT Latest News
-
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know
benzinga · Jun 1, 2026
-
Earnings Scheduled For May 14, 2026
benzinga · May 14, 2026
-
Earnings Scheduled For March 30, 2026
benzinga · Mar 30, 2026
-
Earnings Scheduled For November 13, 2025
benzinga · Nov 13, 2025
RNXT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RNXT.
Price Targets
Consensus target: $6.69
RNXT MoonshotScore
What does this score mean?
The MoonshotScore rates RNXT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Shaun R. Bagai
CEO
Shaun R. Bagai serves as the Chief Executive Officer of RenovoRx, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on oncology and drug delivery systems. He has held leadership positions in various companies, contributing to strategic planning, product development, and commercialization efforts. Bagai's expertise spans across multiple functional areas, including research and development, clinical operations, and business development. He is responsible for guiding RenovoRx's overall strategy and driving the company's growth initiatives.
Track Record: Under Shaun R. Bagai's leadership, RenovoRx has advanced its lead product candidate, RenovoGem, into Phase III clinical trials for locally advanced pancreatic cancer. He has overseen the company's efforts to secure funding and build strategic partnerships. Bagai has also focused on expanding RenovoRx's intellectual property portfolio and strengthening its position in the targeted drug delivery market. His leadership has been instrumental in navigating the challenges of clinical development and regulatory approval processes.
Common Questions About RNXT (Healthcare)
What does RenovoRx, Inc. do?
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of solid tumors. Their lead product candidate, RenovoGem, is a drug-device combination designed for targeted intra-arterial delivery of gemcitabine directly to the tumor site. This approach aims to improve drug concentration within the tumor while reducing exposure to healthy tissues, potentially enhancing treatment efficacy and minimizing side effects for patients with locally advanced pancreatic cancer.
What do analysts say about RNXT stock?
Analyst coverage of RenovoRx (RNXT) is limited due to its small market capitalization and clinical-stage status. Current assessments focus on the potential of RenovoGem and the company's targeted drug delivery technology. Key valuation metrics include the potential market size for pancreatic cancer therapies and the probability of success for RenovoGem in clinical trials. Growth considerations center on the company's ability to secure regulatory approval and commercialize its products. Analyst opinions are subject to change based on clinical trial results and regulatory developments.
What are the main risks for RNXT?
RenovoRx faces significant risks inherent to clinical-stage biotechnology companies. The primary risk is the potential failure of RenovoGem in Phase III clinical trials, which would significantly impact the company's value. Regulatory hurdles and potential delays in obtaining FDA approval also pose substantial risks. Competition from established pharmaceutical companies with greater resources and established market presence is another key concern. Additionally, RenovoRx's limited financial resources and reliance on a single lead product candidate increase its vulnerability to adverse events.
What are the key factors to evaluate for RNXT?
RenovoRx, Inc. (RNXT) holds an AI score of 25/100 (low). Analysts target $6.69 (+606%). Not financial advice.
How frequently does RNXT data refresh on this page?
RNXT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RNXT's recent stock price performance?
RenovoRx, Inc. (RNXT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug-device combination (RenovoGem). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RNXT overvalued or undervalued right now?
Valuing RenovoRx, Inc. (RNXT) requires multiple metrics. Analysts target $6.69 (+606%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RNXT?
Before investing in RenovoRx, Inc. (RNXT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.